TransMedics Group (NASDAQ:TMDX) Posts Earnings Results, Beats Estimates By $0.40 EPS

TransMedics Group (NASDAQ:TMDX) posted its quarterly earnings results on Tuesday. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40, Briefing.com reports. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The business had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. During the same period in the prior year, the company posted ($0.08) EPS. The business’s revenue for the quarter was up 132.9% on a year-over-year basis. TransMedics Group updated its FY 2024 guidance to EPS.

TransMedics Group Trading Up 0.9 %

Shares of TMDX stock traded up $1.06 during trading hours on Thursday, hitting $118.66. The company’s stock had a trading volume of 152,500 shares, compared to its average volume of 741,134. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The business has a fifty day moving average of $83.85 and a 200-day moving average of $75.92. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $124.18.

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,044,932.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Basile sold 7,157 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total transaction of $618,221.66. Following the completion of the transaction, the director now directly owns 8,350 shares of the company’s stock, valued at approximately $721,273. The disclosure for this sale can be found here. Insiders sold 102,078 shares of company stock worth $8,691,221 in the last ninety days. Insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

TMDX has been the topic of several recent analyst reports. Piper Sandler restated an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research report on Wednesday. Oppenheimer boosted their price target on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday. TD Cowen raised their price objective on TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday. Morgan Stanley lifted their price objective on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Finally, Canaccord Genuity Group upped their target price on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $119.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.